Načítá se...
Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis
BACKGROUND: Oral 5‐aminosalicylic (5‐ASA) preparations were intended to avoid the adverse effects of sulfasalazine (SASP) while maintaining its therapeutic benefits. Previously, it was found that 5‐ASA drugs were more effective than placebo but had a statistically significant therapeutic inferiority...
Uloženo v:
| Vydáno v: | Cochrane Database Syst Rev |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley & Sons, Ltd
2016
|
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7045447/ https://ncbi.nlm.nih.gov/pubmed/27158764 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD000544.pub4 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|